Elucid

Predicting and Personalizing the Prevention of heart attacks & strokes

[Elucid @ElucidBio]

A major milestone for Elucid: FFR-IQ™ is now FDA-cleared and commercially available! Read the full announcement: https://t.co/ryCrIdnMQh

We're proud to introduce BioIntegrated FFR-CT, a new approach to noninvasive coronary physiology assessment that integrates coronary anatomy and plaque composition to support more accurate, personalized treatment decisions.
In the ELUCIDATE FFR-CT study, FFR-IQ demonstrated:
· 92.2% sensitivity
· 93.1% specificity
· The highest reported diagnostic performance among FDA-cleared FFR-CT validation studies.¹

Together, FFR-IQ™ and Plaque-IQ™ bring coronary anatomy, plaque biology, and physiology into one comprehensive platform, enabling physicians to better understand both individual lesions and the patient's broader coronary disease from a single CCTA.

📍 Join us at #TCT2026, where results from the ELUCIDATE FFR-CT study will be presented on November 1. Visit us at booth #3424 to learn more.

¹ Elucid FFR-IQ (B.1). FDA 510(k) Summary, K262015. September 29, 2026. Highest reported performance among FDA-cleared FFR-CT validation studies.

#Elucid #FFRIQ #FFRCT #cardiovascularimaging #CCTA #cardiology #precisionmedicine #TCT2026

[Elucid @ElucidBio]

This Veterans Day, we extend our heartfelt gratitude to all veterans, including those within our own Elucid team, for their service, leadership, and unwavering commitment.
Today, we also recognize the families and loved ones whose support and sacrifices are an important part of that service.
Your dedication and contributions continue to inspire us.
Happy Veterans Day from all of us at Elucid.

[Elucid @ElucidBio]

Happy National Radiologic Technology Week!
Behind every high-quality image is a skilled rad tech whose expertise, precision, and dedication make a difference in patient care.

We recognize the essential role the rad techs play in advancing cardiovascular imaging. From ensuring exceptional image quality to supporting accurate, reliable assessments, their work helps make innovative imaging technologies possible.

At Elucid, we're especially proud to celebrate and thank the talented rad techs on our own team, whose clinical expertise, commitment to excellence, and passion for improving patient care contribute to everything we do.

💙 To our rad techs and the entire radiologic technology community: thank you for the incredible work you do every day! 💙

#radtechweek #NRTW2026 #medicalimaging #cardiovascularimaging

[Elucid @ElucidBio]

From TCT to AHA: Following an exciting week at #TCT2026, we're bringing the momentum to American Heart Association #ScientificSessions26 in Chicago! With the recent FDA clearance of FFR-IQ™ and compelling new results from the ELUCIDATE study, we're excited to showcase how Elucid is advancing a more complete approach to coronary artery disease assessment.

Our BioIntegrated FFR-CT approach brings together coronary anatomy and quantitative plaque characteristics to estimate physiology using technology trained against invasive FFR. Together, Plaque-IQ™ and FFR-IQ™ help clinicians move beyond anatomy alone, combining plaque burden, composition, stenosis assessment, and coronary physiology into a more comprehensive view of disease.

📍 Join us at #AHA26 at Booth 3018!
Meet the team and experience our latest technology firsthand.

#ELUCIDATE #FFRCT #CCTA #cardiovascularimaging #PlaqueIQ #FFRIQ

[Elucid @ElucidBio]

That's a wrap at #TCT2026! Thanks to all of the physicians and partners who stopped by to check out our newly FDA-cleared Biolntegrated FFR-CT product, and to chat about the latest performance data from ELUCIDATE! It's been a blast. Until next time... but find us at #AHA2026 and #RSNA2026 fast-approaching right around the corner!

[Elucid @ElucidBio]

A new chapter in FFR-CT: We're proud to announce results from ELUCIDATE, the pivotal validation study supporting FDA clearance of Elucid's FFR-IQ™ technology, presented at #TCT2026!

The international, multicenter study demonstrated:
- 92.9% vessel-level diagnostic accuracy against invasive FFR
- 92.2% sensitivity and 93.1% specificity, the highest reported in an FFR-CT validation study
- Strong performance in the clinical gray zone
Evaluating 491 coronary vessels across 11 U.S. and European institutions, ELUCIDATE highlights the potential of a fundamentally different approach to noninvasive coronary physiology.

Powered by deep learning and trained against invasive FFR, Biolntegrated FFR-IQ brings together coronary anatomy and plaque biology to estimate physiology.

Together with Plaque-IQ™, this represents an important step toward a more complete, personalized understanding of coronary artery disease.

Read the full announcement: https://t.co/AXDl71hx1p

#ELUCIDATE #FFRIQ #FFRCT #CCTA #cardiovascularimaging

[Elucid @ElucidBio]

Have questions from our #TCT2026 sessions or want more hands-on time? We’re at booth 3424 to chat! Come by to learn how our BioIntegrated FFR-CT and its features can support PCI planning.

#interventionalcardiology #cardiology #ELUCIDATE

[Elucid @ElucidBio]

🫀 Two exciting sessions. One big day at #TCT2026!

We're bringing plaque biology and coronary physiology into the spotlight TODAY at TCT! Join us for two sessions exploring how AI-powered imaging is advancing our understanding of coronary disease.

🔬 TCT AI Lab 3 | 12:20–1:50 PM PT
Real World Applications of AI: AI-Powered CT for Interventional Procedures

Featuring new findings from ELUCIDATE, the pivotal validation study of Elucid's FDA-cleared FFR-IQ™ technology, demonstrating impressive diagnostic performance against invasive FFR. Presented by @amir_ahmadi__.

🫀 Physiology Pavilion | 2:00–3:30 PM PT AND 4:00-5:30 PM PT
Integrating Plaque Biology and BioIntegrated FFR-CT for Lesion-Level Risk Assessment
Hands-on session with @ziadalinyc, @hect2701, and @amir_ahmadi__ as they explore the integration of anatomy, plaque biology, and physiology for a more complete view of coronary disease.

And don't forget to stop by Elucid Booth 3424 to see Plaque-IQ™ and FFR-IQ™ in action!

Lesion-Level Risk → Patient-Level Impact.

#ELUCIDATE #FFRCT #CCTA #interventionalcardiology

[Elucid @ElucidBio]

🫀 Get hands-on with the future of coronary imaging at #TCT2026!
Join Drs. @ziadalinyc, @hect2701, and @amir_ahmadi__ for an interactive training session exploring how plaque biology and BioIntegrated FFR-CT come together to advance lesion-level risk assessment and help guide interventional decisions.

📅 Sunday, November 1 | 2:00–3:30 AND 4:00-5:30 PM PT
📍 Physiology Pavilion | TCT 2026

Experience how anatomy, biology, and physiology can provide a more complete picture of coronary disease.
🔗 https://t.co/GVDXjcAmzx

#TCT2026 #FFRCT #CCTA #cardiovascularimaging

[Elucid @ElucidBio]

🧠 This World Stroke Day, we're throwing it back to #SCCT2026, where Dr. Robert Pelberg, SVP of Medical Affairs, chatted with Viktor Zarev of @Cardiac_Wire to discuss the evolving role of advanced plaque imaging and what it could mean for more personalized cardiovascular care, including stroke care.

Plaque-IQ™ is uniquely indicated for use in both coronary and carotid arteries and uses CT angiography to quantify and characterize carotid plaque, including lipid-rich plaque, a feature associated with vascular risk. Connect with us today to learn more about how you can implement Plaque-IQ into your stroke program.

#WorldStrokeDay #cardiovascularimaging

[Elucid @ElucidBio]

A new chapter in FFR-CT: We're bringing exciting new data to #TCT2026! Join @amir_ahmadi__ as he introduces findings from ELUCIDATE, the pivotal validation study supporting FDA clearance of FFR-IQ™.

Discover how Elucid's BioIntegrated FFR-CT approach brings coronary anatomy and plaque biology together to assess physiology—with impressive diagnostic performance, including in the challenging clinical “gray zone.”

TCT AI Lab 3: AI-Powered CT for Interventional Procedures
Validation of a BioIntegrated, Deep Learning FFR-CT Model Against Invasive FFR
Sunday, November 1 | 12:20–1:50 PM PT

Don't miss the opportunity to hear the latest findings and explore what's next for AI-powered coronary imaging.

Lesion-Level Risk → Patient-Level Impact.
Visit us at Booth 3424!

#ELUCIDATE #FFRCT #CCTA #cardiovascularimaging

[Heart_SCCT @Heart_SCCT]

Free sponsored webinar | CCTA 3.0: From plaque to precision: Connecting lesion-level risk with personalized patient therapy | Wednesday, October 28 at 1 pm ET | Sponsored by @ElucidBio

Register: https://t.co/itYuiBl8Pj

[Elucid @ElucidBio]

What if you could see beyond stenosis to better understand which lesions are truly limiting coronary blood flow?

Join Elucid at #TCT2026 for one of our two hands-on sessions in the Physiology Training Pavilion on November 1!

Experience how FFR-IQ™ and Plaque-IQ™ bring coronary anatomy, plaque biology, and physiology together from a single CCTA, providing a more comprehensive picture of coronary disease to help inform invasive evaluation, revascularization decisions, and personalized patient care.

Discover how better insights before the cath lab can support more precise decisions in the cath lab. Have follow up questions from the session? Visit us at booth 3424 for 1:1 time.

📍 TCT Physiology Training Pavilion | November 1 2PM PT and 4PM PT

https://t.co/lyJEzvSpfo

#TCT2026 #interventionalcardiology #FFRCT #CCTA #PrecisionMedicine

[Cardiovascular Research Foundation @crfheart]

🔥 Less watching. More doing.

The #TCT2026 Training Pavilions put you in the action with hands-on training, expert guidance, and the latest cath lab technologies.

��� Learn it. Practice it. Own it. https://t.co/Xg2cqNwcqO

#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD @m1chaella_alex @CathWhisperer @caldera_99 @SinaDaneshMD @CAESmedmd @Julio_Farjat @GolzarianH @JyotiJain_MD @Shikha_Cardio @DrBilal_khan @KrutarthKPandya @Shoaib9702 @IoannisSkalidis @Sticchi_Alex @ricosuruagy @ladyheart_md @AnaClaraVi75147 @anast_apost @padideh_daneii @MAnisHaider @Rushil_Vasudev

[Elucid @ElucidBio]

Register here: https://t.co/XsRfHQujet

🫀 Join Drs. @GreggWStone, @amir_ahmadi__, and @PraveenRangana9 for our upcoming sponsored webinar THIS WEDNESDAY at 1PM ET, hosted by Society of Cardiovascular Computed Tomography!

Hear how emerging approaches to coronary imaging are connecting plaque biology, physiology, and lesion-level risk with more personalized treatment strategies, including the evolving roles of systemic medical therapy and focal intervention.

Can't join us live? Register at the link above to get the recording sent to your inbox.
See you there!

#cardiology #precisionmedicine #yesCCT

[Elucid @ElucidBio]

We're headed to #TCT2026 in San Diego!
Visit us at Booth 3424 to see how Plaque-IQ™ and BioIntegrated FFR-IQ™ bring anatomy, biology, and physiology together in one comprehensive view of coronary disease.

Sessions to note:
🔬 TCT AI Lab 3 | 12:20–1:50 PM
Real World Applications of AI: AI-Powered CT for Interventional Procedures
Featuring a lecture by Jagat Narula, MD, PhD.

🫀 Training Pavilions | 2:00–3:30 PM & 4:00–5:30 PM
Integrating Plaque Biology and BioIntegrated FFR-CT for Lesion-Level Risk Assessment: Hands-on sessions featuring Amir Ahmadi, MD; Hiram G. Bezerra, MD, PhD; and Hector M. Garcia-Garcia, MD, PhD.

We look forward to connecting with the interventional cardiology community and advancing the conversation around the future of coronary imaging!

#TCT2026 #FFRCT #CCTA #interventionalcardiology #cardiovascularIimaging

[Elucid @ElucidBio]

Join Dr. Amir Ahmadi alongside renowned interventional cardiologist Dr. Gregg Stone for an upcoming sponsored webinar hosted by SCCT on October 28, 1PM ET:

CCTA 3.0: From Plaque to Precision Connecting Lesion-Level Risk with Personalized Patient Therapy
Together, they'll explore how emerging approaches to coronary imaging are connecting plaque biology, physiology, and lesion-level risk with more personalized treatment strategies, including the evolving roles of systemic medical therapy and focal intervention. Moderated by Dr. Praveen Ranganath, this discussion will examine the latest evidence and what it could mean for the future of cardiovascular care.

📅 Wednesday, October 28, 2026
🕐 1:00 PM ET 🔗 Register now: https://t.co/XsRfHQujet

Thank you@Heart_SCCT! #CCTA #SCCT #cardiovascularimaging #precisionmedicine #interventionalcardiology

[Elucid @ElucidBio]

👋 We're thrilled to welcome Mark Miller to Elucid, as we continue expanding access to our cardiovascular imaging technology! He joins us at an exciting point in our growth as we expand commercialization, strengthen our partnerships across the cardiovascular community, and continue our mission to advance more personalized cardiovascular care.

Read the news here: https://t.co/4NVu0HvMuL

#cardiovascularimaging #cardiology #medtech #leadership

[Elucid @ElucidBio]

Come see us at #NASCI2026 today for a hands-on look at Elucid’s CT analysis software offering plaque analysis and BioIntegrated FFR-CT*!

#CCTA #cardiovascularimaging #atherosclerosis #cardiology

*FFR-CT is under FDA review.

[Elucid @ElucidBio]

#VPM2026 was simply stellar, as always. We’re still reflecting on the ideas, science, and conversations that came out of this year’s meeting. Bringing together experts from across the field to openly exchange perspectives on vulnerable plaque, atherosclerosis, and the future of cardiovascular care is what makes VPM such a valuable forum.

Thank you to everyone who shared their expertise, challenged conventional thinking, and left us with new ideas and inspiration to bring back to our work at Elucid 🫀🧠

Stay tuned for our presentations from the meeting!

#vulnerableplaque #cardiovascularimaging #atherosclerosis #CCTA

[Elucid @ElucidBio]

Elucid is proud to support and exhibit at @NASCISociety Annual Meeting, September 26–29 in Denver.

Stop by our booth for a hands-on look at our latest developments and see how we’re advancing CCTA beyond anatomy alone, bringing together anatomy, plaque biology, and physiology for a more complete view of coronary disease.

We’re looking forward to connecting with the cardiovascular imaging community, sharing ideas, and demonstrating what becomes possible with Elucid.
See you at NASCI!

Lesion-Level Risk → Patient-Level Impact

#NASCI2026 #CCTA #cardiacCT #cardiovascularimaging #cardiology